136310-64-0

Basic information

• Product Name: Scopine-2,2-dithienyl glycolate
• Synonyms: SCOPINE-2,2-DITHIENYL GLYCOLATE;2-thiopheneacetic acid, a-hydroxy-a-2th ( Di(2-thienyl) Glycolate );N-DeMethyl TiotropiuM;α-Hydroxy-α-2-thienyl-2-thiopheneacetic Acid (1α,2β,4β,5α,7β)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl Ester;Scopine di(2-thienyl)glycolate scopine-2-dithienyl glycolate;Tiotropium EP Impurity B;2-Thiopheneacetic acid, -hydroxy--2-thienyl-, (1,2,4,5,7);(1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl 2-hydroxy-2,2-dithiophen-2-ylacetate
• CAS NO: 136310-64-0
• Molecular Formula: C₁₈H₁₉NO₄S₂
• Molecular Weight: 377.483
• EINECS: 1533716-785-6
• Product Categories: TIOTROPIUM BROMIDE;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Tiotropium Bromide Intermediates
• Mol File: 136310-64-0.mol
• Article Data: 19

Chemical Properties

• Melting Point: 138-140°C
• Boiling Point: 542.3 ºC at 760 mmHg
• Flash Point: 281.7 ºC
• Appearance: /
• Density: 1.48 g/cm³
• Vapor Pressure: 1.37E-12mmHg at 25°C
• Refractive Index: 1.687
• Storage Temp.: -20°C Freezer
• PKA: 10.32±0.29(Predicted)
• CAS DataBase Reference: Scopine-2,2-dithienyl glycolate(CAS DataBase Reference)
• NIST Chemistry Reference: Scopine-2,2-dithienyl glycolate(136310-64-0)
• EPA Substance Registry System: Scopine-2,2-dithienyl glycolate(136310-64-0)

Safety Data

• Hazardous Substances Data: 136310-64-0(Hazardous Substances Data)

Usage

Description

Scopine-2,2-dithienyl glycolate is an organic compound.?It is off-white solid. The melting point is 138-140°C. The storage temperature is -20°C. Scopine-2,2-dithienyl glycolate is one of the reaction intermediates in the preparation of tiotropium bromide, which is a highly effective anticholinergic agent and widely used for treatment of asthma and/or chronic obstructive pulmonary disease (COPD) (chronic obstructive pulmonary disease).

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 136310-64-0 differently. You can refer to the following data:
1. Scopine Di(2-thienylglycolate) (Tiotropium EP Impurity B) is a precursor to Tiotropium Bromide.
2. Precursor to Tiotropium Bromide.

InChI:InChI=1/C18H19NO4S2/c1-19-11-8-10(9-12(19)16-15(11)23-16)22-17(20)18(21,13-4-2-6-24-13)14-5-3-7-25-14/h2-7,10-12,15-16,21H,8-9H2,1H3

Upstream product

• 136310-66-2 (1R,3S,5S)-2'-hydroxy-2',2'-di(thiophen-2''-yl)acetic acid 8-methyl-8-azabicyclo[3.2.1]oct-6-en-3-yl ester 
• 22150-33-0 (1R,3S,5S)-3'-hydroxy-2'-phenylpropionic acid 8-methyl-8-azabicyclo[3.2.1]oct-6-en-3-yl ester 
• 20513-09-1 (1R,3S,5S)-8-methyl-8-azabicyclo[3.2.1]oct-6-en-3-ol 
• 672-21-9 (+/-)-Scopolamine hydrobromide 
• 26447-85-8 hydroxy-di-thiophen-2-yl-acetic acid methyl ester 
• 498-45-3 scopine 
• 85700-55-6 6exo,7exo-epoxy-tropane-3endo-ol; scopine; hydrochloride 
• 1449372-70-6 (1α,2β,4β,5α,7β)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^2,4]nonan-7-ol oxalate 
• 22143-95-9 tropenol 
• 1003-09-4 2-bromothiophene 
• 51-34-3 scopolamine 
• 1454836-37-3 C₁₀H₁₂ClNO₄ 
• 5713-61-1 thiophen-2-yl magnesium bromide 

Downstream Products

• 1256081-14-7 C₁₀H₁₅O₄S^(1-)*C₁₉H₂₂NO₄S₂⁽¹⁺⁾ 
• 139404-48-1 tiotropium bromide 

Relevant articles and documents

Crystal Structures of Tiotropium Bromide and Its Monohydrate in View of Combined Solid-state Nuclear Magnetic Resonance and Gauge-Including Projector-Augmented Wave Studies

Tiotropium bromide is an anticholinergic bronchodilator used in the management of chronic obstructive pulmonary disease. The crystal structures of this compound and its monohydrate have been previously solved and published. However, in this paper, we showed that those structures contain some major errors. Our methodology based on combination of the solid-state nuclear magnetic resonance (NMR) spectroscopy and quantum mechanical gauge-including projector-augmented wave (GIPAW) calculations of NMR shielding constants enabled us to correct those errors and obtain reliable structures of the studied compounds. It has been proved that such approach can be used not only to perform the structural analysis of a drug substance and to identify its polymorphs, but also to verify and optimize already existing crystal structures.

NMR study on (1α, 2β, 4β, 5α, 7β)-7-[(hydroxydi-2-thienylacetyl) oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo [3.3.1.02,4] nonane bromide monohydrate

The structure of (1α, 2β, 4β, 5α, 7β)-7-[(hydroxydi-2-thienylacetyl) oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo [3.3.1.02,4] nonane bromide monohydrate was studied using 1D and 2D NMR techniques. Complete NMR assignments of the compound were obtained using DEPT, H-H COSY, as well as HMQC and HMBC heteronuclear correlation techniques.

Preparation method of tiotropium bromide

The invention provides a preparation method of tiotropium bromide, which comprises the following steps: (1) reacting a compound of a formula I with a compound of a formula II with an alkaline compound to obtain a compound of a formula III, wherein R is methyl, ethyl, isopropyl or tert-butyl, (2) reacting a halogenating agent of the compound of the formula III with a catalyst to obtain a compound of a formula IV, reacting the compound of the formula IV with an alkali to obtain a compound V, wherein X is Cl, Br or I, and (3) reacting the compound of the formula V with methyl bromide to obtain the tiotropium bromide. According to the method, the defect that vanadium pentoxide and hydrogen peroxide-urea are used as epoxidation agents when tropine is used as a raw material to prepare tiotropium bromide in the prior art is overcome, the reaction safety is improved, and meanwhile, the yield of cyclized products is increased.

A tiotropium bromide intermediate preparation method

The invention relates to a preparation method of a tiotropium bromide intermediate, that is, scopine-2,2-di(2-thienyl)glycolate. The method is characterized in that Lewis acid is used as a catalyst, and scopine and 2,2-di(2-thienyl)methyl glycolate are stirred and react with each other in an organic solvent at the temperature of 50-120 DEG C to produce the scopine-2,2-di(2-thienyl)glycolate, wherein the organic solvent is selected from one or more of non-alcohol, non-carboxylic and non-ester organic solvents.